A Phase 1 interventional study of CBD and Placebo in Osteopenia, sponsored by Canopy Growth Corporation. Terminated at 1 site in United States. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Canopy Growth Corporation · Phase 1, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Bone Diseases, Metabolic with a site in United States — 16 open to participants now, 21 under way, 1 of them phase 3. Bone Diseases, Metabolic · United States.
Among the 217 studies in Bone Diseases, Metabolic with a site in United States, this one is the 165th largest by enrollment of the 171 interventional ones that give a count, is one of 8 that started in 2022, is one of 16 in phase 1, and was the 201st registered.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
Browse Bone Diseases, Metabolic studies →16 of the 217 studies in Bone Diseases, Metabolic with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Tufts Medical Center · Sites in United States
Ages 50+
AO Innovation Translation Center · Sites in United States, Australia, Brazil and 11 more countries
Ages 18+
San Diego State University · Sites in United States
Women only
Texas A&M University · Sites in United States
Ages 18–45 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 50 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 39 · Phase 4 28
First in 1992; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 66 across the 171 interventional studies, 61 across the 45 observational. Of the 180 that completed or were terminated, 82 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 217 have an industry lead sponsor. The 10 most frequent:
Canopy Growth Corporation is the lead sponsor of 10 studies on the registry; none are open to participants now.
Canopy Growth Corporation has 1 study filed under Bone Diseases, Metabolic — fewer than ten, so there is no comparison to draw.
4 of the studies in Bone Diseases, Metabolic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04954664University of Alabama at BirminghamRidge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor | 2026-12 |
| NCT03374215National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | 2026-12-31 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07763509Cornell UniversityCalcium-Rich Food Versus Calcium Carbonate for Bone Health | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 217 studies in Bone Diseases, Metabolic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg CBD per day
Drug: CBD
300 mg CBD per day
Drug: CBD
Placebo
Other: Placebo
CBD
Placebo
Safety and Tolerability: Adverse Events/Serious Adverse Events
Adverse Events/Serious Adverse Events
Time frame: Week 4
Safety and Tolerability: Adverse Events/Serious Adverse Events
Adverse Events/Serious Adverse Events
Time frame: Week 8
Safety and Tolerability: Adverse Events/Serious Adverse Events
Adverse Events/Serious Adverse Events
Time frame: Week 12
Safety and Tolerability: Alanine aminotransferase (ALT)
Alanine aminotransferase
Time frame: Week 4
Safety and Tolerability: Alanine aminotransferase (ALT)
Alanine aminotransferase
Time frame: Week 12
Safety and Tolerability: Aspartate aminotransferase (AST)
Aspartate aminotransferase
Time frame: Week 4
Safety and Tolerability: Aspartate aminotransferase (AST)
Aspartate aminotransferase
Time frame: Week 12
Safety and Tolerability: Total bilirubin
Total bilirubin
Time frame: Week 4
Safety and Tolerability: Total bilirubin
Total bilirubin
Time frame: Week 12
Safety and Tolerability: Blood pressure
Blood pressure - Systolic and diastolic blood pressure
Time frame: Week 4
Safety and Tolerability: Blood pressure
Blood pressure - Systolic and diastolic blood pressure
Time frame: Week 12
Safety and Tolerability: Heart rate
Heart rate
Time frame: Week 4
Safety and Tolerability: Heart rate
Heart rate
Time frame: Week 12
Serum CTx
Serum CTx
Time frame: Week 4
Serum CTx
Serum CTx
Time frame: Week 12
Serum P1NP
Serum P1NP
Time frame: Week 4
Serum P1NP
Serum P1NP
Time frame: Week 12
Serum Osteocalcin
Serum Osteocalcin
Time frame: Week 4
Serum Osteocalcin
Serum Osteocalcin
Time frame: Week 12
Serum Bone-specific alkaline phosphatase
Serum Bone-specific alkaline phosphatase
Time frame: Week 4
Serum Bone-specific alkaline phosphatase
Serum Bone-specific alkaline phosphatase
Time frame: Week 12
Ran from May 2022 to primary completion in Sep 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Canopy Growth Corporation